Johnson & Johnson Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse

By |2025-07-13T07:27:34-07:00July 13th, 2025|Brief Bulletins from the Field, We Know Psychiatry|

Johnson & Johnson recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for lumateperone (Caplyta®), based on long-term data supporting its safety and efficacy in preventing relapse in schizophrenia. Caplyta (42 mg) is a once-daily oral atypical antipsychotic currently approved [...]

Autoimmune Diseases Linked to Increased Risk for Mood Disorders

By |2025-07-04T07:31:21-07:00July 4th, 2025|Brief Bulletins from the Field, We Know Psychiatry|

A study of 1.5 million UK adults found that autoimmune diseases are linked to a nearly twofold increase in the risk for mood disorders such as depression, anxiety, and bipolar disorder compared with the general population. The research, published in BMJ Mental Health, highlights the importance of regular mental health screenings [...]

Semaglutide May Lower Dementia Risk in T2 Diabetes

By |2025-07-04T07:22:13-07:00July 4th, 2025|Brief Bulletins from the Field, We Know Psychiatry|

Semaglutide, a medication for type 2 diabetes (T2D), is associated with a 20%-46% reduced risk for Alzheimer's disease-related dementia compared with other antidiabetic drugs. A study analyzed electronic health records of over 1.7 million US adults with T2D, focusing on dementia diagnoses over three years. Semaglutide showed a stronger protective [...]

New Guidelines Aim to Standardize Psychedelic Clinical Trials

By |2025-06-30T07:21:38-07:00June 30th, 2025|Articles in Press, We Know Psychiatry|

An international panel of 89 experts from 17 countries has developed new guidelines—Reporting of Setting in Psychedelic Clinical Trials (ReSPCT)—to standardize how psychedelic clinical trials report 'set and setting,' the mindset and environment in which psychedelic experiences occur. Published in Nature Medicine, the guidelines outline 30 variables across four key [...]

Weekly Oral Risperidone Pill Shows Promise in Schizophrenia

By |2025-06-30T07:11:08-07:00June 30th, 2025|Brief Bulletins from the Field, We Know Psychiatry|

A Phase 3 clinical trial has shown that LYN-005—a once-weekly oral capsule formulation of risperidone—achieves comparable bioavailability and symptom control to daily dosing in patients with schizophrenia or schizoaffective disorder. Conducted at five sites across the U.S. and enrolling 83 participants, the study was stopped early following positive interim results. [...]

Early Psychological Therapy Improves Post-Stroke Depression and Anxiety

By |2025-06-30T07:12:26-07:00June 30th, 2025|Brief Bulletins from the Field, We Know Psychiatry|

Psychological therapy has been shown to significantly alleviate depression and anxiety in stroke survivors, particularly when initiated within six months of the stroke event. In a study involving over 7,000 adults in England, 71% experienced a reliable improvement in symptoms, while 49% achieved reliable recovery. Patients who began therapy more [...]

Synthetic psilocybin demonstrates a significant reduction in treatment-resistant depression symptoms

By |2025-06-30T07:13:46-07:00June 30th, 2025|Brief Bulletins from the Field, We Know Psychiatry|

A Phase 3 clinical trial of COMP360, a synthetic formulation of psilocybin, showed a significant reduction in symptoms of treatment-resistant depression. Conducted at 32 sites across the U.S. with 258 participants, the study found that a single 25 mg dose led to greater symptom improvement on the Montgomery-Åsberg Depression Rating [...]

Two New Studies Explore Risk Prediction for Postpartum Mental Health Conditions

By |2025-06-11T08:57:49-07:00June 11th, 2025|Brief Bulletins from the Field, We Know Psychiatry|

Two new studies examining mental health risks postpartum were published online in the American Journal of Psychiatry in conjunction with Maternal Mental Health Awareness Month and the 2025 Annual Meeting of the American Psychiatric Association (APA). One study sought to estimate the risk of postpartum depression in people without a [...]

Novel Blood Test Could Help Diagnose and Track Alzheimer’s

By |2025-04-10T07:17:36-07:00April 10th, 2025|Brief Bulletins from the Field, We Know Psychiatry|

A novel blood test that detects a key biomarker for Alzheimer’s disease (AD) could help physicians more accurately determine the presence and track disease progression. The test measures levels of the protein MTBR-tau243 — microtubule-binding region of tau containing the residue 243 — a biomarker of tau tangles in the [...]

New 48-Week Remission Data on Ingrezza for the Treatment of TD

By |2025-04-01T07:06:32-07:00April 1st, 2025|Brief Bulletins from the Field, We Know Psychiatry|

Neurocrine Biosciences presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia (TD) among most patients treated with once-daily valbenazine (Ingrezza) capsules, at the 2025 Psychiatry Update Conference in Chicago.1  The conference was first reported in Psychiatric Times "These findings further establish Ingrezza as a [...]

Go to Top